PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) including programmed cell death 1 (PD-1) and its ligand (PD-L1) inhibitors have significantly improved the prognosis and shifted the treatment paradigm in advanced NSCLC.